Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer

A randomized trial of 3 vs 4 g/m 2 of CY

C. H. Weaver, Lee Schwartzberg, B. Zhen, C. Franco, M. Moore, R. Smith, L. White, A. Van Amburg, B. Hazelton, C. D. Buckner

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m 2 with docetaxel 100 mg/m 2 , in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m 2 of CY. The median yield of CD34 + cells from all patients was 11.06 x 10 6 /kg (range, 0.03-84.77) from a median of two aphereses (range, 1-7); 6.52 x 10 6 CD34 + cells/kg/apheresis (range, 0.01-52.07). Target CD34 + cell doses ≥ 2.5 and ≥ 5.0 x 10 6 /kg were achieved in 89% and 79%, respectively. There were no statistically significant differences in CD34 + cell yields or target CD34 + cell doses achieved following 3 or 4 g/m 2 of CY. Patients with only one prior chemotherapy regimen yielded a median of 12.82 x 10 6 CD34 + cells/kg/apheresis compared to 5.85 for those receiving ≥ 2 regimens (P = 0.03). It was concluded that the combination of docetaxel, 100 mg/m 2 , CY 3 g/m 2 without mesna could be administered with acceptable toxicity with collection of adequate quantities of PBSC from the majority of patients.

Original languageEnglish (US)
Pages (from-to)421-425
Number of pages5
JournalBone Marrow Transplantation
Volume23
Issue number5
DOIs
StatePublished - Jan 1 1999
Externally publishedYes

Fingerprint

docetaxel
Cyclophosphamide
Breast Neoplasms
Blood Component Removal
Mesna
Peripheral Blood Stem Cells

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer : A randomized trial of 3 vs 4 g/m 2 of CY. / Weaver, C. H.; Schwartzberg, Lee; Zhen, B.; Franco, C.; Moore, M.; Smith, R.; White, L.; Van Amburg, A.; Hazelton, B.; Buckner, C. D.

In: Bone Marrow Transplantation, Vol. 23, No. 5, 01.01.1999, p. 421-425.

Research output: Contribution to journalArticle

Weaver, C. H. ; Schwartzberg, Lee ; Zhen, B. ; Franco, C. ; Moore, M. ; Smith, R. ; White, L. ; Van Amburg, A. ; Hazelton, B. ; Buckner, C. D. / Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer : A randomized trial of 3 vs 4 g/m 2 of CY. In: Bone Marrow Transplantation. 1999 ; Vol. 23, No. 5. pp. 421-425.
@article{d9c92167bfc644da9271f42cbdcecb6f,
title = "Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer: A randomized trial of 3 vs 4 g/m 2 of CY",
abstract = "The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m 2 with docetaxel 100 mg/m 2 , in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m 2 of CY. The median yield of CD34 + cells from all patients was 11.06 x 10 6 /kg (range, 0.03-84.77) from a median of two aphereses (range, 1-7); 6.52 x 10 6 CD34 + cells/kg/apheresis (range, 0.01-52.07). Target CD34 + cell doses ≥ 2.5 and ≥ 5.0 x 10 6 /kg were achieved in 89{\%} and 79{\%}, respectively. There were no statistically significant differences in CD34 + cell yields or target CD34 + cell doses achieved following 3 or 4 g/m 2 of CY. Patients with only one prior chemotherapy regimen yielded a median of 12.82 x 10 6 CD34 + cells/kg/apheresis compared to 5.85 for those receiving ≥ 2 regimens (P = 0.03). It was concluded that the combination of docetaxel, 100 mg/m 2 , CY 3 g/m 2 without mesna could be administered with acceptable toxicity with collection of adequate quantities of PBSC from the majority of patients.",
author = "Weaver, {C. H.} and Lee Schwartzberg and B. Zhen and C. Franco and M. Moore and R. Smith and L. White and {Van Amburg}, A. and B. Hazelton and Buckner, {C. D.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701599",
language = "English (US)",
volume = "23",
pages = "421--425",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Mobilization of peripheral blood stem cells with docetaxel and cyclophosphamide (CY) in patients with metastatic breast cancer

T2 - A randomized trial of 3 vs 4 g/m 2 of CY

AU - Weaver, C. H.

AU - Schwartzberg, Lee

AU - Zhen, B.

AU - Franco, C.

AU - Moore, M.

AU - Smith, R.

AU - White, L.

AU - Van Amburg, A.

AU - Hazelton, B.

AU - Buckner, C. D.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m 2 with docetaxel 100 mg/m 2 , in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m 2 of CY. The median yield of CD34 + cells from all patients was 11.06 x 10 6 /kg (range, 0.03-84.77) from a median of two aphereses (range, 1-7); 6.52 x 10 6 CD34 + cells/kg/apheresis (range, 0.01-52.07). Target CD34 + cell doses ≥ 2.5 and ≥ 5.0 x 10 6 /kg were achieved in 89% and 79%, respectively. There were no statistically significant differences in CD34 + cell yields or target CD34 + cell doses achieved following 3 or 4 g/m 2 of CY. Patients with only one prior chemotherapy regimen yielded a median of 12.82 x 10 6 CD34 + cells/kg/apheresis compared to 5.85 for those receiving ≥ 2 regimens (P = 0.03). It was concluded that the combination of docetaxel, 100 mg/m 2 , CY 3 g/m 2 without mesna could be administered with acceptable toxicity with collection of adequate quantities of PBSC from the majority of patients.

AB - The purpose of this study was to develop a regimen of docetaxel, cyclophosphamide (CY) and filgrastim for mobilization of peripheral blood stem cells (PBSC) in patients with metastatic breast cancer (n = 66). A phase I trial of CY 2, 3 or 4 g/m 2 with docetaxel 100 mg/m 2 , in consecutive cohorts of four patients each, did not reveal any dose-limiting toxicities and subsequent patients were randomized to receive 3 or 4 g/m 2 of CY. The median yield of CD34 + cells from all patients was 11.06 x 10 6 /kg (range, 0.03-84.77) from a median of two aphereses (range, 1-7); 6.52 x 10 6 CD34 + cells/kg/apheresis (range, 0.01-52.07). Target CD34 + cell doses ≥ 2.5 and ≥ 5.0 x 10 6 /kg were achieved in 89% and 79%, respectively. There were no statistically significant differences in CD34 + cell yields or target CD34 + cell doses achieved following 3 or 4 g/m 2 of CY. Patients with only one prior chemotherapy regimen yielded a median of 12.82 x 10 6 CD34 + cells/kg/apheresis compared to 5.85 for those receiving ≥ 2 regimens (P = 0.03). It was concluded that the combination of docetaxel, 100 mg/m 2 , CY 3 g/m 2 without mesna could be administered with acceptable toxicity with collection of adequate quantities of PBSC from the majority of patients.

UR - http://www.scopus.com/inward/record.url?scp=0033051560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033051560&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701599

DO - 10.1038/sj.bmt.1701599

M3 - Article

VL - 23

SP - 421

EP - 425

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 5

ER -